Trial Profile
The clinical observational study of Apatinib 425mg Joint docetaxel for the second-line treatment of advanced lung squamous carcinoma
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 16 May 2017
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 16 May 2017 New trial record